A retrospective, multi-institution analysis presented at the 2026 Society for Neuro-Oncology/ASCO CNS Metastases conference reported intracranial activity for tarlatamab in small cell lung cancer patients with brain metastases, including groups with prior stereotactic radiosurgery and whole-brain radiotherapy. Among 36 evaluable patients, overall physician-assessed intracranial objective response rate was 38.9%, with a disease control rate of 61.1%. The active subgroup showed an intracranial ORR of 33.3%, while the study also addressed practical questions on whether CNS radiation can be given alongside a T-cell engager and whether treatment continuation is feasible after isolated CNS progression. For developers of bispecifics and other immune cell therapies, the data adds to the growing evidence base on CNS management in real-world cohorts where pivotal trials often under-enroll active brain metastases.